News | March 10, 2026
AbbVie reports promising early results for novel obesity therapy ABBV-295
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
DiaMedica said it plans to launch the trial later in 2026
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The company announced positive topline data from the Phase II ZUPREME-1 trial
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Subscribe To Our Newsletter & Stay Updated
